On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), ...

Eli Lilly said this morning that its experimental obesity pill orforglipron fell short of expectations in a late-stage trial, delivering 11.2% weight loss over 72 weeks — less than the 15% to 21% ...

Fortinet, AppLovin, Airbnb, Duolingo and more stock were making big moves Thursday after the companies reported quarterly ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly, a renowned drug manufacturer, stated that its GLP-1 pill, orforglipron, assisted individuals in reducing 12.4% of their weight following 72 weeks in a late-stage study.The company ...

Eli Lilly shares fell as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...

At the same time, Trump's hint of a carveout for coming duties on semiconductors boosted tech for a second consecutive day.

A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially ...

Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Drug regulatory agencies in Germany and Australia have added warnings that atomoxetine can trigger violent or suicidal thoughts—sparking urgent concern over its long‑term use in children and adults.

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 ...